SALT LAKE CITY, UT – September 22, 2009 – Nanostart-held BioMicro Systems announces the appointment of Rob Parry as President and Chief Operating Officer.
Mr. Parry will be focused on expanding sales of the MAUI Microarray Product Suite, as well as launching a new line of products for the cytogenetics market. IGOR™, an "Automated Lab Assistant" for processing FISH, WISH, Blots and other slide-based applications, will be available Fall 2009.
BioMicro Systems is a private company that serves the life sciences community by developing and marketing biological research products based on its proprietary microfluidic and microarray technologies.
Mr. Parry has been serving as Chief Operating Officer and Vice President of Manufacturing at BioMicro Systems since February of 2007. Prior to BioMicro Systems, Mr. Parry held top level manufacturing positions in several instrument and consumable businesses, including Hewlett Packard, Agilent Technologies, Fluidigm, and Nanosys. His innovative and effective leadership at BioMicro Systems has led to ISO 9001 certification of the organization, and cost-effective manufacturing processes with consistent high quality and availability of products. In addition to his manufacturing responsibilities at BioMicro, Mr. Parry directed product development efforts and is a co-inventor of both the new IGOR system as well as the successful new design of the MAUI Wash System.
Mr. Parry added, "I am excited to take the lead of the BioMicro Systems team. I see great near term opportunities for our new products and applications. The IGOR system will be the Company's first medical device sold into the clinical market, introducing the Company to a whole new customer base."
Mr. Parry received a B.S.M.E. from Cal Poly, San Luis Obispo, and an M.S. from MIT in Operations Management and Technology Innovation.
About Nanostart:
Nanostart AG is the world’s leading nanotechnology investment company. The Frankfurt-based company provides venture capital financing for nanotechnology companies in various growth phases. It also provides the benefits of its experience and expertise to developers of financial instruments and to investors in the nanotechnology sector. For further information about the company, please visit www.nanostart.de.
About BioMicro Systems, Inc.:
BioMicro Systems, Inc. is a private company focused on the development and commercialization of biological research products based on its proprietary microfluidic and microarray technologies. More company information can be found at www.biomicro.com.
Disclaimer:
This notice constitutes neither an offer to sell nor a solicitation of offers to purchase or subscribe to securities. There will be no public offering of securities of Nanostart AG in conjunction with the existing listing of its shares in the “Entry Standard” segment of the regulated unofficial market (Freiverkehr) on the Frankfurt Stock Exchange. This notice does not constitute a securities prospectus. Neither this notice nor the information contained within is intended for direct or indirect distribution within the United States of America, Canada, Australia or Japan.
Media contact:
Nanostart AG
Public Relations
Dr. Hans Joachim Dürr
Goethestrasse 26-28
D-60313 Frankfurt
Germany
phone: +49 (0)69-21 93 96 111
fax: +49 (0)69-21 93 96 122
e-mail:
This e-mail address is being protected from spambots. You need JavaScript enabled to view it
